-

DermTech Management to Present at Upcoming Investor Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management will present at the following upcoming conferences:

  • Cowen 42nd Annual Health Care Conference
    Presenting on Tuesday, March 8, 2022 at 12:50 p.m. Eastern Time
  • Oppenheimer 32nd Annual Healthcare Conference
    Presenting on Tuesday, March 15, 2022 at 3:20 p.m. Eastern Time

Interested parties may access the live webcasts of the presentations and, for 90 days following the Cowen and Oppenheimer conferences, the archived webcasts of the presentations through the “Investor Relations” section of DermTech’s website at: www.DermTech.com.

About DermTech:
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech's mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech's investor relations site at: www.dermtech.com.

Contacts

DermTech
Sarah Dion
sdion@dermtech.com
858.450.4222

ICR Westwicke IR
Caroline Corner, PhD
caroline.corner@westwicke.com
415.202.5678

DermTech, Inc.

NASDAQ:DMTK

Release Versions

Contacts

DermTech
Sarah Dion
sdion@dermtech.com
858.450.4222

ICR Westwicke IR
Caroline Corner, PhD
caroline.corner@westwicke.com
415.202.5678

More News From DermTech, Inc.

DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced a favorable coverage policy from Highmark Inc. (Highmark). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, West Virginia, Delaware and New York. The Pigmented Lesion Assay (PLA), the foundational assay of the DMT, is an innovative, non-invasi...

DermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline Operations

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced restructuring actions that are intended to prioritize the significant growth opportunities for the DermTech Melanoma Test (DMT), streamline operations, suspend pipeline programs and significantly reduce overall operating expenses. Following a detailed review of its growth opportunities and operations, DermTech...

ECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT)

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that ECRI completed its evaluation of the Pigmented Lesion Assay (PLA), the foundational assay for the DermTech Melanoma Test (DMT), and changed its rating from ‘Inconclusive’ to ‘Somewhat Favorable’. ECRI is an independent, nonprofit organization focused on healthcare technology evaluation and safety to impr...
Back to Newsroom